CPT® Code 91308

Deleted

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

The CPT® Code 91308 refers to a specific vaccine designed to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as coronavirus disease (COVID-19). This vaccine utilizes a novel approach by employing messenger RNA (mRNA) technology encapsulated in lipid nanoparticles (LNP). The mRNA contained in the vaccine encodes the spike protein of the coronavirus, which is a critical component that the virus uses to enter human cells. Upon administration, the mRNA instructs the body's cells to produce copies of the spike protein, prompting the immune system to recognize it as a foreign entity. This recognition triggers an immune response, leading to the production of antibodies that can neutralize the virus if the individual is exposed in the future. The vaccine is specifically formulated for intramuscular use and is preservative-free, ensuring safety and efficacy for pediatric populations. It is important to note that this code is designated for the supply of the Pfizer two-dose pediatric vaccine, intended for children aged 6 months to 4 years, with doses administered at least 21 days apart. The preparation of the vaccine involves diluting it with preservative-free normal saline to achieve the correct dosage of 3 mcg per 0.2 mL, differing from the adult formulation, which includes additional buffering agents for stabilization. The actual administration of the vaccine is reported separately using the appropriate administration code, based on the dosage given.